Peritia

Peritia Bio is a preclinical-stage biotechnology company dedicated to developing transformative therapies for neurodegenerative disorders, with an initial focus on Parkinson’s disease. The company leverages deep insights into the genetic and molecular drivers of lysosomal dysfunction, specifically targeting the GBA1 pathway to design precision small molecule therapeutics. By restoring glucocerebrosidase (GCase) activity, Peritia aims to address the underlying pathology of GBA-associated Parkinson's and potentially other synucleinopathies. Founded by leading experts in neurology and lysosomal biology from Northwestern University, the company is translating breakthrough academic research into clinical applications. Peritia Bio is backed by prominent life science venture capital firms, including F-Prime Capital and Eight Roads Ventures.